Cancer News and Research

Latest Cancer News and Research

Canary Foundation researcher awarded $11.5M NIH POCRC SPORE grant for early detection ovarian cancer research

Canary Foundation announces its first researcher, Nicole Urban, Sc.D., and collaborators are awarded 5 years of renewed funding from the National Institutes of Health (NIH) for the Pacific Ovarian Cancer Research Consortium (POCRC) Specialized Programs of Research Excellence (SPORE). The SPORE grant will allow Dr. Urban and fellow researchers to continue work in locating tumor markers and developing blood tests to identify and assess risk and early detection of ovarian cancer. The Listwin Family Foundation and Canary Foundation have been funding Dr. Urban's research since 2002.

3 Feb 2010

Research shows DNA looping can impact gene expression

University of Michigan researchers have shown that tension on DNA molecules can affect gene expression---the process at the heart of biological function that tells a cell what to do.

3 Feb 2010

Veran Medical Technologies receives two FDA clearances to expand the use of ig4 Navigation platform

Veran Medical Technologies announced today that it has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platform.

3 Feb 2010

Study could provide potential therapeutic strategies for treating prostate cancer

Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, according to new data from researchers at UT Southwestern Medical Center.

3 Feb 2010

Vizioncore makes $500 donation to fight breast cancer

Vizioncore Inc. today announced the company is making a $500 donation to 26.2 with Donna - The National Marathon to Finish Breast Cancer. The charitable organization is the only U.S. marathon dedicated solely to raising funds to end breast cancer.

3 Feb 2010

EpiCept regains compliance with Nasdaq minimum bid price requirement

EpiCept Corporation today announced that Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement in Listing Rule 5550(a)(2) and met the requirements of the Nasdaq Listing Qualification Panel (the “Panel”) decision dated November 2, 2009. Accordingly, the Panel has determined to continue the listing of the Company’s common stock on The Nasdaq Stock Market.

3 Feb 2010

VIDAZA prolongs survival in AML patients

The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology concludes VIDAZA (azacitidine) “prolongs survival and is well tolerated” in patients with acute myeloid leukemia (AML) - an aggressive form of leukemia that in many cases progresses from MDS.

3 Feb 2010

Students collect money to support vital cancer research initiatives

Millions of students across the country soon will share more than their "two cents" as they collect spare change to benefit The Leukemia & Lymphoma Society's (LLS) School & Youth campaign during Olive Garden's 16th-annual Pasta for Pennies program.

3 Feb 2010

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.

3 Feb 2010

NeoMatrix, Novation sign new technology agreement

NeoMatrix, Inc., developers of the innovative HALO® Breast Pap Test, has been awarded a new technology agreement by Novation, the supply contracting company of VHA Inc, University HealthSystem Consortium (UHC) and Provista.

2 Feb 2010

Obama's budget includes a tempered vision of health reform

Democrats' health overhaul efforts are stalled in Congress, but President Obama's 2011 budget offers a "modest" back-up plan, the Associated Press reports. "The budget released Monday contains lots of respectable ideas to squeeze savings, expand coverage and improve quality, but no ambitious change that launches the nation on a path to health care for all."

2 Feb 2010

GenSpera’s G-115 anti-cancer drug awarded US patent

GenSpera, Inc. announced that its patent application, entitled “Tumor Activated Prodrugs,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera’s second anti-cancer drug in development.

2 Feb 2010

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

2 Feb 2010

BC Cancer Foundation's campaign passes significant threshold with major donation for cancer care

Join the BC Cancer Foundation and community leaders for an exciting announcement which will significantly impact the lives of cancer patients and their families throughout Vancouver Island, the Gulf Islands and beyond.

2 Feb 2010

Long-term harmful effects of BPA exposure: Cereplast lauds FDA's demand for additional study

Cereplast, Inc., manufacturer of proprietary bio-based sustainable plastics, applauds the Food and Drug Administration (FDA) for demanding increased study of the long-term effects of Bisphenol A (BPA) exposure.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

Researchers identify 1.1M base pairs of DNA in soybean genome

In 2009, soybeans represented an almost $30 billion industry in the U.S. alone, making soybeans the second-most profitable crop next to corn. Worldwide, soybeans have been used in human foods and livestock feed for centuries and have been a key component in industrial products, such as plastics and soy biodiesel, an environmentally friendly fuel.

2 Feb 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on ALL

Treating acute lymphocytic leukemia (ALL) can bring many challenges, particularly in the adult population. To optimally manage this disease in adult patients, healthcare professionals must understand and identify characteristics of high-risk disease, utilize best strategies for preventing central nervous system relapse, and recognize the important role of post-remission hematopoietic stem cell transplantation in ALL therapy.

2 Feb 2010

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Elbit Imaging ("Elbit Imaging" "Company") announced today that it intends to restructure its bio-tech and medical holdings (InSightec - 60%, and Gamida Cell - 28%; both on a fully diluted basis) under a wholly-owned Elbit Imaging subsidiary and to offer shares of such subsidiary in a public offering on the Tel Aviv Stock Exchange ("IPO").

2 Feb 2010

Cancer News and Research

Latest Cancer News and Research

Canary Foundation researcher awarded $11.5M NIH POCRC SPORE grant for early detection ovarian cancer research

Research shows DNA looping can impact gene expression

Veran Medical Technologies receives two FDA clearances to expand the use of ig4 Navigation platform

Study could provide potential therapeutic strategies for treating prostate cancer

Vizioncore makes $500 donation to fight breast cancer

EpiCept regains compliance with Nasdaq minimum bid price requirement

VIDAZA prolongs survival in AML patients

Students collect money to support vital cancer research initiatives

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

NeoMatrix, Novation sign new technology agreement

Obama's budget includes a tempered vision of health reform

GenSpera’s G-115 anti-cancer drug awarded US patent

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

BC Cancer Foundation's campaign passes significant threshold with major donation for cancer care

Long-term harmful effects of BPA exposure: Cereplast lauds FDA's demand for additional study

Cytheris broadens patent protection for recombinant human interleukin-7

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Researchers identify 1.1M base pairs of DNA in soybean genome

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on ALL

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in